Placing of Shares

RNS Number : 3074S
SkinBioTherapeutics PLC
15 November 2021
 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Placing of shares held by major shareholder
 

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today been informed that its major shareholder, OptiBiotix Health Plc ("OptiBiotix") has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share.  Prior to the sale OptiBiotix held 36,138,569 ordinary shares representing 23.1% of the Company and following this sale, will continue to hold 32,502,206 ordinary shares in SkinBioTherapeutics representing 20.7% of the Company.

Optibiotix, Cenkos Securities Plc and the Company have entered into a lock-in and orderly market agreement pursuant to which Optibiotix has undertaken to the Company and to Cenkos that, subject to the customary exceptions: (i) it will not until the first anniversary of the sale dispose of the Ordinary Shares that it holds during such period; and (ii) it will only dispose of such Ordinary Shares during the 12 month period following such first anniversary through the Company's Nominated Adviser and Broker so as to ensure an orderly market in the Shares.

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"We are pleased that this placing is enabling us to bring in new institutional shareholders and broadening the shareholder base in an orderly fashion. The Company is going from strength to strength with its newly launched first commercial product, AxisBiotix-Ps™, so it is important to attract new investors who are keen to come on board to support us in the next stage of the Company's development, as a commercial entity."

-Ends-

For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Nathan Billis 

Tel: +44 (0) 20 7457 2020

SkinBio@instinctif.com

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AsixBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEBCBDBBBBDGBS
UK 100

Latest directors dealings